Neurovascular devices company Rapid Medical revealed on Tuesday the receipt of US FDA clearance for the Comaneci device under the new temporary coil embolization assist devices category.
The company added that the Comaneci device, which is the first and only device in a new temporary coil embolization assist devices category, is the first-ever adjustable, fully-visible aneurysm remodelling device. It acts as a temporary bridge used to aid in the coiling processes while minimising the risk of coil protrusion or prolapse.
According to the company, the Comaneci device is the only temporary coiling assist device that does not require parent vessel occlusion during coiling procedure or the need for long-term antiplatelet medication in case of permanent stenting. It is the only non-vessel-occluding temporary intracranial coiling embolization assist device.
To date, the Comaneci have been successfully used in about 3,000 procedures outside the US, concluded the company.
Abbott and NACHC launch nationwide Food for Health initiative
Galmed reports positive preclinical results for Aramchol in prostate cancer
Galderma receives EU approval for Restylane Shaype facial shaping injectable
Sisram Medical introduces Titanium Prime treatment concept in Hong Kong SAR
Proteotype unveils Alchemi platform for blood-based multi-cancer test Enlighten
Insulet expands European footprint with Omnipod 5 and Omnipod Discover launch in Spain
Frontier IP portfolio company InSignals wins EU grant and launches Parkinson's app
PharmaResearch to acquire CG USA to support North American expansion of REJURAN Cosmetics
United Therapeutics wins FDA approval for LungFX ex vivo lung perfusion device